Skip to main content
. 2024 Nov 7;13(22):1847. doi: 10.3390/cells13221847

Figure 1.

Figure 1

Establishment of the olaparib-resistant BRCA1m UWB1.289 cell line. (A) Schematic protocol for generating olaparib-resistant derivative of UWB1.289 (UWB-OlaJR) is shown. W, weeks; d, days. (B) Representative images showed similar cell morphology between parental UWB1.289 and olaparib-resistant UWB-OlaJR. (C) Cell growth was examined by XTT assay. UWB1.289 and UWB-OlaJR cells were treated with olaparib at indicated doses (0–40 µM) for 5 days. The value 0 was plotted as 0.31 µM for better visualization since 0 cannot be plotted on logarithmic scale. (D) Cell growth was examined by colony-forming assay. Cells were treated with olaparib at indicated doses for 10 days. (E) Olaparib-resistant UWB-OlaJR cell lines were maintained in the regular medium without olaparib for up to 8 weeks and subjected to cell growth assays. (F) Cells were treated with cisplatin at indicated doses for 5 days. Clinically attainable concentrations for each respective agent are denoted by the dotted line on each graph. All experiments were repeated in triplicate. Data are shown as mean ± SD. ****, p < 0.0001; ***, p < 0.001; *, p < 0.05.